Laurent Décosterd

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


322 publications

Sous presse | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | ...
Population pharmacokinetic analysis of doravirine in real-world people with HIV.
Thoueille P., Delarive L., Cavassini M., Buclin T., Decosterd L.A., Marzolini C., Girardin F.R., Guidi M., Swiss HIV Cohort Study British journal of clinical pharmacology. Peer-reviewed.
Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures.
Thoueille P., Cavassini M., Guidi M., Buclin T., Girardin F.R., Decosterd L.A., Marzolini C., 2024/02. Open forum infectious diseases, 11 (2) pp. ofae023. Peer-reviewed.
Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data.
Berton M., Bettonte S., Stader F., Decosterd L., Tarr P.E., Livio F., Cavassini M., Braun D.L., Kusejko K., Hachfeld A. et al., 2024/01/25. Clinical infectious diseases, 78 (1) pp. 98-110. Peer-reviewed.
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.
Thoueille P., Saldanha S.A., Schaller F., Choong E., Munting A., Cavassini M., Braun D., Günthard H.F., Kusejko K., Surial B. et al., 2024/01. The Lancet regional health. Europe, 36 p. 100793. Peer-reviewed.
 
Therapeutic drug monitoring of TB drugs
Choong Eva, Marzolini Catia, Girardin François, Decosterd Laurent, Köhler Niklas, 2023/12. dans Translational TB-Forum, Inselspital Bern, December 11, 2023. Peer-reviewed.
Development and validation of a multiplex HPLC-MS/MS assay for the monitoring of JAK inhibitors in patient plasma.
Tachet J., Versace F., Mercier T., Buclin T., Decosterd L.A., Choong E., Girardin F.R., 2023/11/15. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1230 p. 123917. Peer-reviewed.
A Single-Run HPLC-MS Multiplex Assay for Therapeutic Drug Monitoring of Relevant First- and Second-Line Antibiotics in the Treatment of Drug-Resistant Tuberculosis.
Köhler N., Karaköse H., Grobbel H.P., Hillemann D., Andres S., König C., Kalsdorf B., Brehm T.T., Böttcher L., Friesen I. et al., 2023/10/27. Pharmaceutics, 15 (11) p. 2543. Peer-reviewed.
Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study.
Thoueille P., Delfraysse M., Andre P., Buclin T., Decosterd L.A., Fedeli C., Ustero P., Calmy A., Guidi M., Swiss HIV Cohort Study, 2023/09/27. BMC pharmacology & toxicology, 24 (1) p. 47. Peer-reviewed.
Supplementum 272: Abstracts of the Annual meeting of the Swiss Society of Gastroenterology, the Swiss Society of Visceral Surgery, the Swiss Association for the Study of the Liver and the Swiss Society of Endoscopy Nurses and Associates
Juillerat Pascal, Tachet Jérémie, Mercier Thomas, Versace François, Guidi Monia, Buclin Thierry, Decosterd Laurent, Choong Eva, Girardin François, 2023/09/11., Annual meeting of the Swiss Society of Gastroenterology , the Swiss Society of Visceral Surgery, the Swiss Association for the Study of the Liver, the Swiss Society of Endoscopy Nurses and Associates pp. s3511 dans Swiss Medical Weekly, François. Peer-reviewed, SMW Supporting Association.
 
A Highly Sensitive HPLC-MS/MS MethodFor Multiplex Analysis Of Janus KinaseInhibitors In Plasma
Tachet J., Mercier T., André P., Guidi M., Buclin T., Decosterd L., Choong E., Girardin F., 2023/07. dans 19th World Congress of Basic and Clinical Pharmacology (WCP), Glasgow, July 2023.
Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration.
Thoueille P., Alves Saldanha S., Desfontaine V., Kusejko K., Courlet P., Andre P., Cavassini M., Decosterd L.A., Buclin T., Guidi M. et al., 2023/06/01. The Journal of antimicrobial chemotherapy, 78 (6) pp. 1433-1443. Peer-reviewed.
 
Simultaneous kinetics of oral vorinostat in plasma and cerebrospinal fluid in a patient with cutaneous T-cell lymphoma with CNS involvement.
Papadopoulou V., Degrauwe N., Decosterd L.A., Buclin T., Cairoli A., 2023/06. International journal of clinical pharmacology and therapeutics, 61 (6) pp. 270-272. Peer-reviewed.
 
Utilité du TDM des anti-rétroviraux: passé, présent, futur
Choong Eva, Thoueille Paul, Cavassini M., Decosterd Laurent, 2023/05/04. dans Association pour la ormation en Analyses de Biologie Spécialisée (AFABS) - Journée de formation du 4 mai 2023 - Lausanne . Peer-reviewed.
 
Pretomanid-resistant tuberculosis.
Koehler N., Andres S., Merker M., Dreyer V., John A., Kuhns M., Krieger D., Choong E., Verougstraete N., Zur Wiesch P.A. et al., 2023/05. The Journal of infection, 86 (5) pp. 520-524. Peer-reviewed.
 
Interest of therapeutic drug monitoring: lumacaftor, ivacaftor, tezacaftor, and elexacaftor.
Choong Eva, Sauty A., Koutsokera A., Blanchon S., André Pascal, Decosterd L., 2023/03. dans Journée mucoviscidose romande March 2023 - Lausanne. Peer-reviewed.
Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies.
Biniecka P., Matsumoto S., Belotti A., Joussot J., Bai J.F., Majjigapu S.R., Thoueille P., Spaggiari D., Desfontaine V., Piacente F. et al., 2023/02/16. Molecules, 28 (4) p. 1897. Peer-reviewed.
Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine.
Desfontaine V., Guinchard S., Marques S., Vocat A., Moulfi F., Versace F., Huser-Pitteloud J., Ivanyuk A., Bardinet C., Makarov V. et al., 2023/01/15. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1215 p. 123555. Peer-reviewed.
 
An interprofessional medication adherence program to optimize adherence to oral anticancer therapies: a randomized-controlled trial
Bandiera C., Cardoso E., Locatelli I., Digklia A., Zaman K., Diciolla A., Cristina V., Stravodimou A., Lopez V.A., Dolcan A. et al., 2023., 26th International Society for Medication Adherence (ESPACOMP) Conference p. 269 dans International Journal of Clinical Pharmacy. Peer-reviewed.
Development and validation of a liquid chromatography coupled to tandem mass spectrometry method for the monitoring of temsavir plasma concentrations in people living with HIV.
Thoueille P., Seybold U., Decosterd L.A., Desfontaine V., 2023/01/01. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1214 p. 123575. Peer-reviewed.
Precision oncology by point-of-care therapeutic drug monitoring and dosage adjustment of conventional cytotoxic chemotherapies: A perspective.
Briki M., André P., Thoma Y., Widmer N., Wagner A.D., Decosterd L.A., Buclin T., Guidi M., Carrara S., 2023. Pharmaceutics, 15 (4) p. 1283. Peer-reviewed.
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
Schmulenson E., Bovet C., Theurillat R., Decosterd L.A., Largiadèr C.R., Prost J.C., Csajka C., Bärtschi D., Guckenberger M., von Moos R. et al., 2022/12. British journal of clinical pharmacology, 88 (12) pp. 5336-5347. Peer-reviewed.
Treatment-emergent adverse events and antiseizure medication actual drug load.
Prétat T., Aícua-Rapún I., André P., Lebon S., Rossetti A.O., Decosterd L.A., Buclin T., Novy J., 2022/12. Epilepsy & behavior, 137 (Pt A) p. 108980. Peer-reviewed.
Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study.
Aebi-Popp K., Kahlert C.R., Crisinel P.A., Decosterd L., Saldanha S.A., Hoesli I., Martinez De Tejada B., Duppenthaler A., Rauch A., Marzolini C. et al., 2022/11/28. The Journal of antimicrobial chemotherapy, 77 (12) pp. 3436-3442. Peer-reviewed.
 
A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis.
Mercier T., Desfontaine V., Cruchon S., Da Silva Pereira Clara J.A., Briki M., Mazza-Stalder J., Kajkus A., Burger R., Suttels V., Buclin T. et al., 2022/11/15. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1211 p. 123456. Peer-reviewed.
 
Corrigendum to "Validation and clinical application of a multiplex high performance liquid chromatography - Tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections" [J. Chromatogr. B 1157 (2020) 122160].
Decosterd L.A., Mercier T., Ternon B., Cruchon S., Guignard N., Lahrichi S., Pesse B., Rochat B., Burger R., Lamoth F. et al., 2022/11/15..
Valproate in status epilepticus: Correlation between loading dose, serum levels, and clinical response.
Vijiala S., André P., Buclin T., Decosterd L.A., Rossetti A.O., Novy J., 2022/09. European journal of neurology, 29 (9) pp. 2607-2611. Peer-reviewed.
Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
Choong E., Sauty A., Koutsokera A., Blanchon S., André P., Decosterd L., 2022/08/11. Pharmaceutics, 14 (8) p. 1674. Peer-reviewed.
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.
Thoueille P., Alves Saldanha S., Schaller F., Munting A., Cavassini M., Braun D., Günthard H.F., Kusejko K., Surial B., Furrer H. et al., 2022/07/29. Pharmaceutics, 14 (8) p. 1588. Peer-reviewed.
Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer.
Courlet P., Cardoso E., Bandiera C., Stravodimou A., Zurcher J.P., Chtioui H., Locatelli I., Decosterd L.A., Darnaud L., Blanchet B. et al., 2022/06/21. Pharmaceutics, 14 (7) p. 1317. Peer-reviewed.
Development of an assay by liquid chromatography coupled to tandem mass spectrometry for thiopurines drugs in whole blood and application for their Therapeutic Drug Monitoring
Nguyen N., Da Silva Pereira Clara J. A., Mercier T., Desfontaines V., Ceppi F., Moradpour D., Chtioui H., André P., Buclin T., Decosterd L. A. et al., 2022/06/01. dans 6ème Congrès de printemps de la Société Suisse de Médecine Interne Générale du 1er juin 2022.
Therapeutic drug monitoring of cefepime in a non-critically ill population: retrospective assessment and potential role for model-based dosing.
Suttels V., André P., Thoma Y., Veuve F., Decosterd L., Guery B., Buclin T., 2022/04. JAC-antimicrobial resistance, 4 (2) pp. dlac043. Peer-reviewed.
HDLs extract lipophilic drugs from cells.
Zheng A., Dubuis G., Georgieva M., Mendes Ferreira C.S., Serulla M., Del Carmen Conde Rubio M., Trofimenko E., Mercier T., Decosterd L., Widmann C., 2022/03/01. Journal of cell science, 135 (5) pp. jcs258644. Peer-reviewed.
Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation.
Dao K., Fuchs A., André P., Giannoni E., Decosterd L.A., Marchetti O., Asner S.A., Pfister M., Widmer N., Buclin T. et al., 2022/02/02. The Journal of antimicrobial chemotherapy, 77 (2) pp. 457-465. Peer-reviewed.
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection.
Thoueille P., Choong E., Cavassini M., Buclin T., Decosterd L.A., 2022/02/02. The Journal of antimicrobial chemotherapy, 77 (2) pp. 290-302. Peer-reviewed.
 
Ensuring Sufficient Trough Plasma Concentrations for Broad-Spectrum Beta-Lactam Antibiotics in Children With Malignancies: Beware of Augmented Renal Clearance!
André P., Diezi L., Dao K., Crisinel P.A., Rothuizen L.E., Chtioui H., Decosterd L.A., Diezi M., Asner S., Buclin T., 2022. Frontiers in pediatrics, 9 p. 768438. Peer-reviewed.
 
Safety, tolerability, pharmacokinetic profile and ex-vivo antitubercular acativity of macozinone formulated as spraydredi dispersion (SDD) versus native crystal powder (NCO?: single ascending doses, randomized, placebo-controlled, cross-ouver phase la trial in healthy volunteers
Rothuizen L.E., Ciullini L., Huser-Pitteloud J., Guidi M., Chtioui H., Ivanyuk A., André P., Bardinet C., Decosterd L.A., Spaggiari D. et al., 2022. dans SGAIM/SSMIG 6th Spring Congress Lausanne, June 2022. Primary and Hospital Care 2022: 22 (Suppl. 12), 173.
Therapeutic drug monitoring of newer generation antiseizure medications at the point of treatment failure.
Fluckiger P., Aícua-Rapún I., André P., Rossetti A.O., Decosterd L.A., Buclin T., Novy J., 2022/01. Seizure, 94 pp. 66-69. Peer-reviewed.
 
Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial.
Labhardt N.D., Smit M., Petignat I., Perneger T., Marinosci A., Ustero P., Diniz Ribeiro M.P., Ragozzino S., Nicoletti G.J., Faré P.B. et al., 2021/12. EClinicalMedicine, 42 p. 101188. Peer-reviewed.
 
Therapeutic drug monitoring in a patient with very advanced XDR-TB
Lange C., Köhler N., Choong E., Decosterd L.A., 2021/11/11. dans International Workshop on Clinical Pharmacology of Tuberculosis Drugs.
 
Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial.
Courlet P., Barbieux C., Sculier D., Wandeler G., Stoeckle M., Bernasconi E., Braun D., Vernazza P., Cavassini M., Marinosci A. et al., 2021/11. British journal of clinical pharmacology, 87 (11) pp. 4455-4460. Peer-reviewed.
 
Late Breaking Abstract - Therapeutic drug monitoring in a patient with very advanced XDR-TB
Choong Eva, Decosterd Laurent, 2021/09/05. dans Tuberculosis and non-tuberculous mycobacterial diseases. Peer-reviewed.
 
Seizure freedom and plasma levels of newer generation antiseizure medications.
Aícua-Rapún I., André P., Rossetti A.O., Décosterd L.A., Buclin T., Novy J., 2021/08. Acta neurologica Scandinavica, 144 (2) pp. 202-208. Peer-reviewed.
Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.
Courlet P., Guidi M., Alves Saldanha S., Cavassini M., Stoeckle M., Buclin T., Marzolini C., Decosterd L.A., Csajka C., 2021/07. European journal of clinical pharmacology, 77 (7) pp. 979-987. Peer-reviewed.
 
Saliva therapeutic drug monitoring of the newer anti-epileptic drugs
Choong E., Novy J., Decosterd L., Buclin T., Rossetti A., Stampfli C., Vassalo P., Andre P., Aícua-Rapún I., 2021/04/15., Spring Meeting of the Swiss Society of Pharmacology and Toxicology dans SSPT 2021 Spring Meeting: Abstract Book. Peer-reviewed, Swiss Society of Pharmacology and Toxicology.
Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.
Stader F., Courlet P., Decosterd L.A., Battegay M., Marzolini C., 2021/04. Clinical pharmacology and therapeutics, 109 (4) pp. 1025-1029. Peer-reviewed.
 
A Hyaluronic Acid Hydrogel Loaded with Gentamicin and Vancomycin Successfully Eradicates Chronic Methicillin-Resistant Staphylococcus aureus Orthopedic Infection in a Sheep Model.
Boot W., Schmid T., D'Este M., Guillaume O., Foster A., Decosterd L., Richards R.G., Eglin D., Zeiter S., Moriarty T.F., 2021/03/18. Antimicrobial agents and chemotherapy, 65 (4) pp. e01840-20. Peer-reviewed.
Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV.
Courlet P., Guidi M., Alves Saldanha S., Stader F., Traytel A., Cavassini M., Stoeckle M., Buclin T., Marzolini C., Decosterd L.A. et al., 2021/03. Clinical pharmacokinetics, 60 (3) pp. 379-390. Peer-reviewed.
 
Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly.
Stader F., Courlet P., Kinvig H., Penny M.A., Decosterd L.A., Battegay M., Siccardi M., Marzolini C., 2021/02. Clinical pharmacology and therapeutics, 109 (2) pp. 471-484. Peer-reviewed.
 
Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation.
Stader F., Courlet P., Kinvig H., Battegay M., Decosterd L.A., Penny M.A., Siccardi M., Marzolini C., 2021/02. British journal of clinical pharmacology, 87 (2) pp. 458-470. Peer-reviewed.
Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: Lessons from the CounterCOVID - imatinib study.
Bartelink I.H., Bet P.M., Widmer N., Guidi M., Duijvelaar E., Grob B., Honeywell R., Evelo A., Tielbeek IPE, Snape S.D. et al., 2021. CPT, 10 (12) pp. 1497-1511. Peer-reviewed.
No renal dysfunction or salt and water retention in acute mountain sickness at 4,559 m among young resting males after passive ascent.
Biollaz J., Buclin T., Hildebrandt W., Décosterd L.A., Nussberger J., Swenson E.R., Bärtsch P., 2021/01/01. Journal of applied physiology, 130 (1) pp. 226-236. Peer-reviewed.
 
Optimizing oral targeted anticancer therapies study for patients with solid cancer: Protocol for a randomized controlled medication adherence program along with systematic collection and modeling of pharmacokinetic and pharmacodynamic data.
Bandiera C., Cardoso E., Locatelli I., Digklia A., Zaman K., Diciolla A., Cristina V., Stravodimou A., Lopez V.A., Dolcan A. et al., 2021. JMIR research protocols, 10 (6) pp. e30090. Peer-reviewed.
Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections.
Decosterd L.A., Mercier T., Ternon B., Cruchon S., Guignard N., Lahrichi S., Pesse B., Rochat B., Burger R., Lamoth F. et al., 2020/11/10. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1157 p. 122160. Peer-reviewed.
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Sculier D., Wandeler G., Yerly S., Marinosci A., Stoeckle M., Bernasconi E., Braun D.L., Vernazza P., Cavassini M., Buzzi M. et al., 2020/11. PLoS medicine, 17 (11) pp. e1003421. Peer-reviewed.
Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV.
Courlet P., Decosterd L.A., Alves Saldanha S., Cavassini M., Stader F., Stoeckle M., Buclin T., Marzolini C., Csajka C., Guidi M. et al., 2020/08. Clinical pharmacokinetics, 59 (8) pp. 1037-1048. Peer-reviewed.
 
Real-life management of drug-drug interactions between antiretrovirals and statins.
Courlet P., Livio F., Alves Saldanha S., Scherrer A., Battegay M., Cavassini M., Stoeckle M., Decosterd L.A., Marzolini C., Swiss HIV Cohort Study, 2020/07/01. The Journal of antimicrobial chemotherapy, 75 (7) pp. 1972-1980. Peer-reviewed.
Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
Courlet P., Alves Saldanha S., Cavassini M., Marzolini C., Choong E., Csajka C., Günthard H.F., André P., Buclin T., Desfontaine V. et al., 2020/06. Journal of mass spectrometry, 55 (6) pp. e4506. Peer-reviewed.
 
Aging does not impact drug--drug interaction magnitudes with antiretrovirals.
Stader F., Decosterd L., Stoeckle M., Cavassini M., Battegay M., Saldanha S.A., Marzolini C., Courlet P., and the Swiss HIV Cohort Study, 2020/05/01. AIDS, 34 (6) pp. 949-952. Peer-reviewed.
 
Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease.
Pérez Marín M., Decosterd L.A., Andre P., Buclin T., Mercier T., Murray K., Rizzi M., Meylan P., Jaton-Ogay K., Opota O. et al., 2020/02/28. Journal of the Pediatric Infectious Diseases Society, 9 (1) pp. 96-99. Peer-reviewed.
Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers.
Schantl A.E., Verhulst A., Neven E., Behets G.J., D'Haese P.C., Maillard M., Mordasini D., Phan O., Burnier M., Spaggiari D. et al., 2020/02/05. Nature communications, 11 (1) p. 721. Peer-reviewed.
Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers.
Dao K., Thoueille P., Decosterd L.A., Mercier T., Guidi M., Bardinet C., Lebon S., Choong E., Castang A., Guittet C. et al., 2020/02. Pharmacology research & perspectives, 8 (1) pp. e00558. Peer-reviewed.
 
Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Courlet P., Stader F., Guidi M., Alves Saldanha S., Stoeckle M., Cavassini M., Battegay M., Buclin T., Decosterd L.A., Marzolini C. et al., 2020/01/01. AIDS, 34 (1) pp. 103-108. Peer-reviewed.
The steps to therapeutic drug monitoring: A structured approach illustrated with imatinib
Buclin T., Thoma Y., Widmer N., André P., Guidi M., Csajka C., Decosterd L..A., 2020. Frontiers in Pharmacology, 11 p. 177. Peer-reviewed.
Therapeutic Drug Monitoring of Newer Antiepileptic Drugs: A Randomized Trial for Dosage Adjustment.
Aícua-Rapún I., André P., Rossetti A.O., Ryvlin P., Hottinger A.F., Decosterd L.A., Buclin T., Novy J., 2020/01. Annals of neurology, 87 (1) pp. 22-29. Peer-reviewed.
 
Therapeutic drug monitoring of targeted anticancer protein kinase inhibitors in routine clinical use: A critical review.
Cardoso E., Guidi M., Blanchet B., Schneider M.P., Decosterd L.A., Buclin T., Csajka C., Widmer N., 2020. Therapeutic Drug Monitoring, 42 (1) pp. 33-44. Peer-reviewed.
Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV.
Courlet P., Livio F., Guidi M., Cavassini M., Battegay M., Stoeckle M., Buclin T., Alves Saldanha S., Csajka C., Marzolini C. et al., 2019/12. Open forum infectious diseases, 6 (12) pp. ofz531. Peer-reviewed.
 
Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial.
Braun D.L., Turk T., Tschumi F., Grube C., Hampel B., Depmeier C., Schreiber P.W., Brugger S.D., Greiner M., Steffens D. et al., 2019/10/15. Clinical infectious diseases, 69 (9) pp. 1489-1497. Peer-reviewed.
 
Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.
Courlet P., Guidi M., Glatard A., Alves Saldanha S., Cavassini M., Buclin T., Marzolini C., Eap C.B., Decosterd L.A., Csajka C. et al., 2019/09. British journal of clinical pharmacology, 85 (9) pp. 2022-2032. Peer-reviewed.
 
Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting.
Barcelo C., Aouri M., Courlet P., Guidi M., Braun D.L., Günthard H.F., Piso R.J., Cavassini M., Buclin T., Decosterd L.A. et al., 2019/09/01. The Journal of antimicrobial chemotherapy, 74 (9) pp. 2690-2697. Peer-reviewed.
 
UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV.
Courlet P., Spaggiari D., Desfontaine V., Cavassini M., Alves Saldanha S., Buclin T., Marzolini C., Csajka C., Decosterd L.A., 2019/09/01. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1125 p. 121733. Peer-reviewed.
 
Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence.
Courlet P., Decosterd L.A., Brown J.A., Alves Saldanha S., Marzolini C., Cavassini M., Stoeckle M., Csajka C., Labhardt N.D., Calmy A. et al., 2019/08/01. The Journal of antimicrobial chemotherapy, 74 (8) pp. 2468-2470. Peer-reviewed.
 
Severe rosuvastatin accumulation with rhabdomyolysis due to drug interactions and low cardiac output syndrome.
Previsdomini M., Graziano E., Decosterd L., Courlet P., Perren A., Ceschi A., 2019/07. British journal of clinical pharmacology, 85 (7) pp. 1616-1618. Peer-reviewed.
 
Isavuconazole brain penetration in cerebral aspergillosis.
Lamoth F., Mercier T., André P., Pagani J.L., Pantet O., Maduri R., Guery B., Decosterd L.A., 2019/06/01. The Journal of antimicrobial chemotherapy, 74 (6) pp. 1751-1753. Peer-reviewed.
Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children.
Guidi M., Mercier T., Aouri M., Decosterd L.A., Csajka C., Ogutu B., Carn G., Kiechel J.R., 2019/04/18. Malaria journal, 18 (1) p. 139. Peer-reviewed.
 
Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy.
Leuppi-Taegtmeyer A.B., Decosterd L., Osthoff M., Mueller N.J., Buclin T., Corti N., 2019/02. Antimicrobial agents and chemotherapy, 63 (2). Peer-reviewed.
Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial.
Sottas O., Guidi M., Thieffry B., Schneider M., Décosterd L., Mueller I., Genton B., Csajka C., Senn N., 2019. PloS one, 14 (2) pp. e0210789. Peer-reviewed.
Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma.
Spaggiari D., Desfontaine V., Cruchon S., Guinchard S., Vocat A., Blattes E., Pitteloud J., Ciullini L., Bardinet C., Ivanyuk A. et al., 2019. PloS one, 14 (5) pp. e0217139. Peer-reviewed.
 
Imatinib Uptake into Cells is Not Mediated by Organic Cation Transporters OCT1, OCT2, or OCT3, But is Influenced by Extracellular pH.
Blanc Mettral J., Faller N., Cruchon S., Sottas L., Buclin T., Schild L., Choong E., Nahimana A., Decosterd L.A., 2019. Drug metabolism letters, 13 (2) pp. 102-110. Peer-reviewed.
Intravenous brivaracetam in status epilepticus: Correlation between loading dose, plasma levels and clinical response.
Aicua-Rapun I., André P., Rossetti A.O., Decosterd L.A., Buclin T., Novy J., 2019/01. Epilepsy research, 149 pp. 88-91. Peer-reviewed.
 
Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Burger R., Guidi M., Calpini V., Lamoth F., Decosterd L., Robatel C., Buclin T., Csajka C., Marchetti O., 2018/12/01. The Journal of antimicrobial chemotherapy, 73 (12) pp. 3413-3422. Peer-reviewed.
Levetiracetam circulating concentrations and response in status epilepticus.
Perrenoud M., André P., Buclin T., Decosterd L.A., Rossetti A.O., Novy J., 2018/11. Epilepsy & behavior, 88 pp. 61-65. Peer-reviewed.
 
High-level artemisinin-resistance with quinine co-resistance emerges in P. falciparum malaria under in vivo artesunate pressure.
Tyagi R.K., Gleeson P.J., Arnold L., Tahar R., Prieur E., Decosterd L., Pérignon J.L., Olliaro P., Druilhe P., 2018/10/01. BMC medicine, 16 (1) p. 181. Peer-reviewed.
 
Comparison against current standards of a DNA aptamer for the label-free quantification of tobramycin in human sera employed for therapeutic drug monitoring.
Tenaglia E., Ferretti A., Decosterd L.A., Werner D., Mercier T., Widmer N., Buclin T., Guiducci C., 2018/09/10. Journal of Pharmaceutical and Biomedical Analysis, 159 pp. 341-347. Peer-reviewed.
Efficacy and safety of continuous infusions with elastomeric pumps for outpatient parenteral antimicrobial therapy (OPAT): an observational study.
Voumard R., Gardiol C., André P., Arensdorff L., Cochet C., Boillat-Blanco N., Decosterd L., Buclin T., de Vallière S., 2018/09/01. The Journal of antimicrobial chemotherapy, 73 (9) pp. 2540-2545. Peer-reviewed.
Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study.
Sculier D., Doco-Lecompte T., Yerly S., Metzner K.J., Decosterd L.A., Calmy A., 2018/06/22. HIV medicine, 19 (8) pp. 572-577. Peer-reviewed.
 
The Antimalarial Drug Artesunate Attenuates Cardiac Injury in A Rodent Model of Myocardial Infarction.
Khan A.I., Kapoor A., Chen J., Martin L., Rogazzo M., Mercier T., Decosterd L., Collino M., Thiemermann C., 2018/06. Shock, 49 (6) pp. 675-681. Peer-reviewed.
 
LC-MS/MS method for the simultaneous analysis of seven antimalarials and two active metabolites in dried blood spots for applications in field trials: Analytical and clinical validation.
Gallay J., Prod'hom S., Mercier T., Bardinet C., Spaggiari D., Pothin E., Buclin T., Genton B., Decosterd L.A., 2018/05/30. Journal of pharmaceutical and biomedical analysis, 154 pp. 263-277. Peer-reviewed.
Appropriateness of malaria diagnosis and treatment for fever episodes according to patient history and anti-malarial blood measurement: a cross-sectional survey from Tanzania.
Gallay J., Mosha D., Lutahakana E., Mazuguni F., Zuakulu M., Decosterd L.A., Genton B., Pothin E., 2018/05/21. Malaria journal, 17 (1) p. 209. Peer-reviewed.
 
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E., Mercier T., Wagner A.D., Homicsko K., Michielin O., Ellefsen-Lavoie K., Cagnon L., Diezi M., Buclin T., Widmer N. et al., 2018/04/15. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1083 pp. 124-136. Peer-reviewed.
<i>In vitro</i> study of new combinations for local antibiotic therapy with calcium sulphate - Near constant release of ceftriaxone offers new treatment options.
Wahl P., Rönn K., Bohner M., Decosterd L.A., Meier C., Schläppi M., Festa S., Gautier E., 2018. Journal of bone and joint infection, 3 (4) pp. 212-221. Peer-reviewed.
Is Penicillin Plus Gentamicin Synergistic Against Sessile Group B Streptococcal Isolates? An <i>in Vivo</i> Study With an Experimental Model of Foreign-Body Infection.
Ruppen C., Mercier T., Grandgirard D., Leib S.L., El Haj C., Murillo O., Decosterd L., Sendi P., 2018. Frontiers in microbiology, 9 p. 919. Peer-reviewed.
Predictors of residual antimalarial drugs in the blood in community surveys in Tanzania.
Gallay J., Pothin E., Mosha D., Lutahakana E., Mazuguni F., Zuakulu M., Decosterd L.A., Genton B., 2018. PloS one, 13 (9) pp. e0202745. Peer-reviewed.
Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy.
Gayi E., Neff L.A., Massana Muñoz X., Ismail H.M., Sierra M., Mercier T., Décosterd L.A., Laporte J., Cowling B.S., Dorchies O.M. et al., 2018. Nature Communications, 9 (1) p. 4848. Peer-reviewed.
 
Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report.
Marzolini C., Decosterd L., Winterfeld U., Tissot F., Francini K., Buclin T., Livio F., 2017/12. British journal of clinical pharmacology, 83 (12) pp. 2835-2838. Peer-reviewed.
Adequate plasma drug concentrations suggest that amoxicillin can be administered by continuous infusion using elastomeric pumps.
Arensdorff L., Boillat-Blanco N., Decosterd L., Buclin T., de Vallière S., 2017/09/01. The Journal of antimicrobial chemotherapy, 72 (9) pp. 2613-2615. Peer-reviewed.
 
Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.
Bartels H., Decosterd L., Battegay M., Marzolini C., 2017/09/01. The Journal of antimicrobial chemotherapy, 72 (9) pp. 2574-2577. Peer-reviewed.
 
Lamotrigine serum levels: Ceiling effect in people with epilepsy in remission?
D'Anto J., Wnuk W., Rossetti A.O., Decosterd L.A., Buclin T., Novy J., 2017/09. Epilepsy & behavior, 74 pp. 41-44. Peer-reviewed.
 
Prevalence of polypharmacy in the Swiss HIV Cohort Study (SHCS). Le futur c’est maintenant !
Courlet P., Cavassini M., Choong E., Csajka C., Marzolini C., Decosterd L., and the Swiss HIV Cohort Study, 2017/05/03. dans SSMIG SSPTC Spring Meeting, Lausanne EPFL.
Antibiotic stability over six weeks in aqueous solution at body temperature with and without heat treatment that mimics the curing of bone cement.
Samara E., Moriarty T.F., Decosterd L.A., Richards R.G., Gautier E., Wahl P., 2017/05. Bone & joint research, 6 (5) pp. 296-306. Peer-reviewed.
Antibiotic stability related to temperature variations in elastomeric pumps used for outpatient parenteral antimicrobial therapy (OPAT).
Voumard R., Van Neyghem N., Cochet C., Gardiol C., Decosterd L., Buclin T., de Valliere S., 2017/05/01. The Journal of antimicrobial chemotherapy, 72 (5) pp. 1462-1465. Peer-reviewed.
 
Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
Aouri M., Barcelo C., Guidi M., Rotger M., Cavassini M., Hizrel C., Buclin T., Decosterd L.A., Csajka C., Swiss HIV Cohort Study, 2017/04. Antimicrobial agents and chemotherapy, 61 (1) p. 10. Peer-reviewed.
 
Is gentamicin necessary in the antimicrobial treatment for group B streptococcal infections in the elderly? An in vitro study with human blood products.
Ruppen C., Decosterd L., Sendi P., 2017/03. Infectious diseases, 49 (3) pp. 185-192. Peer-reviewed.
 
Therapeutic Drug Monitoring in CML treatment - Experience from two reference centers
Choong E., Decosterd L., 2017/01/20. dans European Ponatinib Plasma Testing Workshop, Incyte, Lausanne, Switzerland .
Intravenous lacosamide in status epilepticus: Correlation between loading dose, serum levels, and clinical response.
Perrenoud M., André P., Alvarez V., Stähli C., Decosterd L.A., Rossetti A.O., Novy J., 2017. Epilepsy Research, 135 pp. 38-42. Peer-reviewed.
 
The emerging role of multiplex tandem mass spectrometry analysis for therapeutic drug monitoring and personalized medicine
Decosterd L.A., Widmer N., André P., Aouri M., Buclin T., 2016/11. TrAC Trends in Analytical Chemistry, 84 pp. 5-13. Peer-reviewed.
 
Antitumoral Effect of Sunitinib-eluting Beads in the Rabbit VX2 Tumor Model.
Bize P., Duran R., Fuchs K., Dormond O., Namur J., Decosterd L.A., Jordan O., Doelker E., Denys A., 2016/08. Radiology, 280 (2) pp. 425-435. Peer-reviewed.
Privacy-preserving genomic testing in the clinic: a model using HIV treatment.
McLaren P.J., Raisaro J.L., Aouri M., Rotger M., Ayday E., Bartha I., Delgado M.B., Vallet Y., Günthard H.F., Cavassini M. et al., 2016/08. Genetics in medicine, 18 (8) pp. 814-822. Peer-reviewed.
 
Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.
Barceló C., Gaspar F., Aouri M., Panchaud A., Rotger M., Guidi M., Cavassini M., Buclin T., Decosterd L.A., Csajka C. et al., 2016/07. The Journal of antimicrobial chemotherapy, 71 (7) pp. 1933-1942. Peer-reviewed.
An inhibitor of HIV-1 protease modulates constitutive eIF2α dephosphorylation to trigger a specific integrated stress response.
De Gassart A., Bujisic B., Zaffalon L., Decosterd L.A., Di Micco A., Frera G., Tallant R., Martinon F., 2016. Proceedings of the National Academy of Sciences of the United States of America, 113 (2) pp. E117-E126.
Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection.
Hodgson S.H., Llewellyn D., Silk S.E., Milne K.H., Elias S.C., Miura K., Kamuyu G., Juma E.A., Magiri C., Muia A. et al., 2016. Frontiers in microbiology, 7 p. 1604. Peer-reviewed.
 
In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.
Aouri M., Barcelo C., Ternon B., Cavassini M., Anagnostopoulos A., Yerly S., Hugues H., Vernazza P., Günthard H.F., Buclin T. et al., 2016. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 44 (1) pp. 151-161.
Is Penicillin Plus Gentamicin Synergistic against Clinical Group B Streptococcus isolates?: An In vitro Study.
Ruppen C., Lupo A., Decosterd L., Sendi P., 2016. Frontiers in microbiology, 7 p. 1680. Peer-reviewed.
 
Multigenerational effects of the anticancer drug tamoxifen and its metabolite 4-hydroxy-tamoxifen on Daphnia pulex.
Borgatta M., Waridel P., Decosterd L.A., Buclin T., Chèvre N., 2016. Science of the Total Environment, 545-546 pp. 21-29.
 
Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease.
Vionnet J., Saouli A.C., Pascual M., Stucker F., Decosterd L.A., Moradpour D., Chtioui H., 2016. Journal of Hepatology, 65 (5) pp. 1063-1065. Peer-reviewed.
 
Pharmacokinetic modelling of dialytic clearance in a case of acyclovir intoxication.
Kissling S., Fuchs A., Gobin N., Vogt B., Burnier M., Decosterd L.A., Buclin T., Livio F., 2015/11. International Journal of Antimicrobial Agents, 45 (3) pp. 325-327. Peer-reviewed.
 
Suivi thérapeutique pharmacologique des inhibiteurs de protéines kinases
Buclin Thierry, Csajka Chantal, Guiducci Carlotta, Decosterd Laurent A, 2015/09. Innovations & Thérapeutiques en Oncologie, 1 (1) pp. 12-23.
 
Therapeutic drug monitoring of targeted anticancer therapy.
Decosterd L.A., Widmer N., Zaman K., Cardoso E., Buclin T., Csajka C., 2015/09. Biomarkers In Medicine, 9 (9) pp. 887-893. Peer-reviewed.
 
Multiplex Mass Spectrometry Analysis of Latest-Generation Antiepileptic Drugs: A Clinically Useful Laboratory Tool for Improved Real-Time Patients' Care.
Decosterd LA, Mercier T, André P, Bertholet S, Rothuizen LE, Rossetti AO, Buclin T, 2015/06. Epileptologie, 32 (2) pp. 85-89.
A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Braun D.L., Rauch A., Aouri M., Durisch N., Eberhard N., Anagnostopoulos A., Ledergerber B., Müllhaupt B., Metzner K.J., Decosterd L. et al., 2015. Plos One, 10 (7) pp. e0133028. Peer-reviewed.
 
Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature.
Petit-Jean E., Buclin T., Guidi M., Quoix E., Gourieux B., Decosterd L.A., Gairard-Dory A.C., Ubeaud-Séquier G., Widmer N., 2015. Therapeutic Drug Monitoring, 37 (1) pp. 2-21. Peer-reviewed.
 
Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
Fournier A., Eggimann P., Pagani J.L., Revelly J.P., Decosterd L.A., Marchetti O., Pannatier A., Voirol P., Que Y.A., 2015. Burns, 41 (5) pp. 956-968. Peer-reviewed.
 
Label-free detection of tobramycin in serum by transmission-localized surface plasmon resonance.
Cappi G., Spiga F.M., Moncada Y., Ferretti A., Beyeler M., Bianchessi M., Decosterd L., Buclin T., Guiducci C., 2015. Analytical Chemistry, 87 (10) pp. 5278-5285.
 
Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants
Fuchs A., Giannoni E., Guidi M., Decosterd L.A., Marchetti O., Pfister M., Widmer N., Buclin T., Csajka C., 2015. pp. Abstr. 3505 dans 24th Population Approach Group in Europe (PAGE) Meeting, PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
 
Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants
Fuchs A., Giannoni E., Guidi M., Decosterd L.A., Marchetti O., Pfister M., Widmer N., Buclin T., Csajka C., 2015. dans Nano-Tera Annual Plenary Meeting.
 
Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake.
Schaerer V., Haubitz S., Kovari H., Ledergerber B., Ambrosioni J., Cavassini M., Stoeckle M., Schmid P., Decosterd L., Aouri M. et al., 2015. HIV Medicine, 16 (10) pp. 599-607. Peer-reviewed.
Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report.
Vionnet J., Pascual M., Chtioui H., Giostra E., Majno P.E., Decosterd L.A., Moradpour D., 2015. BMC Gastroenterology, 15 (1) p. 38. Peer-reviewed.
 
The anticancer drug metabolites endoxifen and 4-hydroxy-tamoxifen induce toxic effects on Daphnia pulex in a two-generation study.
Borgatta M., Decosterd L.A., Waridel P., Buclin T., Chèvre N., 2015. Science of the Total Environment, 520 pp. 232-240.
 
Therapeutic Drug Monitoring of Antiepileptic Drugs in the 21st Century
André P., Novy J., Decosterd LA, Buclin T., Rothuizen LE, 2015/01/01. Epileptologie 32 pp. 78-84.
 
Treatment of pleural malignancies by photo-induction combined to systemic chemotherapy: Proof of concept on rodent lung tumors and feasibility study on porcine chest cavities.
Wang X., Gronchi F., Bensimon M., Mercier T., Decosterd L.A., Wagnières G., Debefve E., Ris H.B., Letovanec I., Peters S. et al., 2015. Lasers In Surgery and Medicine, 47 (10) pp. 807-816. Peer-reviewed.
 
A simple, robust and rapid approach to detect carbapenemases in Gram-negative isolates by MALDI-TOF mass spectrometry: validation with triple quadripole tandem mass spectrometry, microarray and PCR.
Vogne C., Prod'hom G., Jaton K., Decosterd L.A., Greub G., 2014. Clinical Microbiology and Infection, 20 (12) pp. O1106-O1112. Peer-reviewed.
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
Gotta V., Widmer N., Decosterd L.A., Chalandon Y., Heim D., Gregor M., Benz R., Leoncini-Franscini L., Baerlocher G.M., Duchosal M.A. et al., 2014. Cancer Chemotherapy and Pharmacology, 74 (6) pp. 1307-1319. Peer-reviewed.
 
High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate.
Mercier T., Tissot F., Gardiol C., Corti N., Wehrli S., Guidi M., Csajka C., Buclin T., Couet W., Marchetti O. et al., 2014. Journal of Chromatography. A, 1369 pp. 52-63. Peer-reviewed.
 
Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.
Gotta V., Bouchet S., Widmer N., Schuld P., Decosterd L.A., Buclin T., Mahon F.X., Csajka C., Molimard M., 2014. Leukemia Research, 38 (7) pp. 764-772. Peer-reviewed.
Low-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis Model.
Perentes J.Y., Wang Y., Wang X., Abdelnour E., Gonzalez M., Decosterd L., Wagnieres G., van den Bergh H., Peters S., Ris H.B. et al., 2014. Translational Oncology, 7 (3) pp. 393-399. Peer-reviewed.
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M., Lubomirov R., Fayet-Mello A., Aouri M., Rotger M., Buclin T., Widmer N., Gatri M., Ledergerber B., Rentsch K. et al., 2014. Journal of Antimicrobial Chemotherapy, 69 (9) pp. 2489-2498. Peer-reviewed.
Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology.
Dahmane E., Boccard J., Csajka C., Rudaz S., Décosterd L., Genin E., Duretz B., Bromirski M., Zaman K., Testa B. et al., 2014. Analytical and Bioanalytical Chemistry, 406 (11) pp. 2627-2640. Peer-reviewed.
 
Shotgun Ecotoxicoproteomics of Daphnia pulex: Biochemical Effects of the Anticancer Drug Tamoxifen.
Borgatta M., Hernandez C., Decosterd L.A., Chèvre N., Waridel P., 2014. Journal of Proteome Research, 14 (1) pp. 279-291.
Towards a new combination therapy for tuberculosis with next generation benzothiazinones.
Makarov V., Lechartier B., Zhang M., Neres J., van der Sar A.M., Raadsen S.A., Hartkoorn R.C., Ryabova O.B., Vocat A., Decosterd L.A. et al., 2014. Embo Molecular Medicine, 6 (3) pp. 372-383. Peer-reviewed.
Intravenous streptomycin dosing regimen in a patient undergoing hemodialysis: Plasma level monitoring and pharmacokinetic simulation
Chtioui H., Zbinden D., Manuel O., Entenza J., Decosterd L.A., Buclin T., 2013/08. pp. e106 dans 11th Conference of the European Association for Clinical Pharmacology and Therapeutics, Clinical Therapeutics.
 
A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.
Aouri M., Calmy A., Hirschel B., Telenti A., Buclin T., Cavassini M., Rauch A., Decosterd L.A., 2013. Journal of Mass Spectrometry, 48 (5) pp. 616-625.
 
Clinical pharmacokinetics of imatinib and its therapeutic relevance
Widmer N., Gotta V., Haouala A., Blanc J., von Mehren M., Duchosal M., Leyvraz S., Csajka C., Decosterd L.A., Buclin T., 2013. pp. 15-43 dans Akhtari M., Elhemaidi I. (eds.) Imatinib: Chemical structure, pharmacology and adverse effects chap. 2, Nova Science Publishers.
 
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: Results from the randomized controlled I-COME Trial
Gotta V., Widmer N., Decosterd L.A., Chalandon Y., Heim D., Benz R., Gregor M., Leoncini-Franscini L., Baerlocher G., Duchosal M. et al., 2013. pp. e6 dans 11th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Clinical Therapeutics. Peer-reviewed.
 
Efavirenz intoxication due to a new CYP2B6 constellation.
Anagnostopoulos A., Rotger M., Aouri M., Kuster S.P., Telenti A., Décosterd L.A., Günthard H.F., 2013. Antiviral Therapy, 18 (5) pp. 739-743.
 
Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.
Staehli Hodel E.M., Csajka C., Ariey F., Guidi M., Kabanywanyi A.M., Duong S., Decosterd L.A., Olliaro P., Beck H.P., Genton B., 2013. Antimicrobial Agents and Chemotherapy, 57 (2) pp. 950-958.
 
Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women.
Fayet-Mello A., Buclin T., Guignard N., Cruchon S., Cavassini M., Grawe C., Gremlich E., Popp K.A., Schmid F., Eap C.B. et al., 2013. Antiviral Therapy, 18 (2) pp. 171-182. Peer-reviewed.
 
Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
Cusini A., Vernazza P.L., Yerly S., Decosterd L.A., Ledergerber B., Fux C.A., Rohrbach J., Widmer N., Hirschel B., Gaudenz R. et al., 2013. Journal of Acquired Immune Deficiency Syndromes, 62 (1) pp. 28-35. Peer-reviewed.
 
Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.
Aouri M., Moradpour D., Cavassini M., Mercier T., Buclin T., Csajka C., Telenti A., Rauch A., Decosterd L.A., 2013. Antimicrobial Agents and Chemotherapy, 57 (7) pp. 3147-3158. Peer-reviewed.
 
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
Lubomirov R., Arab-Alameddine M., Rotger M., Fayet-Mello A., Martinez R., Guidi M., di Iulio J., Cavassini M., Günthard H.F., Furrer H. et al., 2013. Pharmacogenetics and Genomics, 23 (1) pp. 9-18. Peer-reviewed.
Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.
Staehli Hodel E.M., Guidi M., Zanolari B., Mercier T., Duong S., Kabanywanyi A.M., Ariey F., Buclin T., Beck H.P., Decosterd L.A. et al., 2013. Malaria Journal, 12 p. 235. Peer-reviewed.
 
Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.
Haouala A., Widmer N., Guidi M., Montemurro M., Leyvraz S., Buclin T., Eap C.B., Decosterd L.A., Csajka C., 2013. British Journal of Clinical Pharmacology, 75 (4) pp. 1007-1018. Peer-reviewed.
 
The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy.
Dorchies O.M., Reutenauer-Patte J., Dahmane E., Ismail H.M., Petermann O., Patthey- Vuadens O., Comyn S.A., Gayi E., Piacenza T., Handa R.J. et al., 2013. American Journal of Pathology, 182 (2) pp. 485-504.
 
A highly sensitive LC-tandem MS assay for the measurement in plasma and in urine of salbutamol administered by nebulization during mechanical ventilation in healthy volunteers.
Sidler-Moix A.L., Mercier T., Decosterd L.A., Di Paolo E.R., Berger-Gryllaki M., Cotting J., Pannatier A., 2012. Biomedical Chromatography : BMC, 26 (5) pp. 672-680. Peer-reviewed.
 
Antimicrobial Agents
Csajka C., Marchetti O., Manuel O., Decosterd L., Telenti A., 2012. pp. 379-402 dans Anzenbacher P., Zanger U.M. (eds.) Metabolism of Drugs and Other Xenobiotics chap. 14, Wiley-VCH Verlag.
Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy.
Glass T.R., Rotger M., Telenti A., Decosterd L., Csajka C., Bucher H.C., Günthard H.F., Rickenbach M., Nicca D., Hirschel B. et al., 2012/01. Plos One, 7 (1) pp. e29186. Peer-reviewed.
 
Dosage optimization of treatments using population pharmacokinetic modeling and simulation.
Guidi M., Arab-Alameddine M., Rotger M., Aouri M., Telenti A., Decosterd L.A., Buclin T., Csajka C., Swiss HIV Cohort Study, 2012. Chimia, 66 (5) pp. 291-295. Peer-reviewed.
 
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.
Aouri M., Decosterd L.A., Buclin T., Hirschel B., Calmy A., Livio F., 2012. AIDS, 26 (6) pp. 776-778.
 
Impact of tamoxifen dose on tamoxifen and its active metabolites exposure in breast cancer patients: preliminary results from a prospective, open-label trial
Dahmane E., Zaman K., Galmiche Rindisbacher M., Berthod G., Perey L., Bodmer A., Leyvraz S., Eap C., Decosterd L., Buclin T. et al., 2012. pp. 108S dans 80. Jahrestagung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum = Forum Médical Suisse.
 
Inhibiteurs des tyrosines kinases dans la LMC: Guide pratique des interactions médicamenteuses
Widmer N., Decosterd L.A., Nicolini F., Rothuizen L., Réa D., 2012., 2012 80, Editions Scientifiques L & C.
 
Pharmacokinetic (PK)-based dosage individualization of imatinib: evaluation of efficiency and clinical usefulness
Gotta V., Widmer N., Decosterd L.A., Montemurro M., Leyvraz S., Chalandon Y., Heim D., Gregor M., Benz R., Leoncini-Franscini L. et al., 2012. dans 3rd Symposium of the Swiss Clinical Trial Organisation (SCTO), Personalised Medicine in Clinical Research.
 
Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density.
Wang Y., Gonzalez M., Cheng C., Haouala A., Krueger T., Peters S., Decosterd L.A., van den Bergh H., Perentes J.Y., Ris H.B. et al., 2012. Lasers in Surgery and Medicine, 44 (4) pp. 318-324. Peer-reviewed.
 
Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.
Arab-Alameddine M., Fayet-Mello A., Lubomirov R., Neely M., di Iulio J., Owen A., Boffito M., Cavassini M., Günthard H.F., Rentsch K. et al., 2012. Antimicrobial Agents and Chemotherapy, 56 (6) pp. 2959-2966.
Pragmatic approach for interpreting antiretroviral drug concentrations based on a systematic review of population pharmacokinetic studies
Arab-Alameddine M., Buclin T., Guidi M., Widmer N., Decosterd L.A., Csajka C., 2012. pp. Abstr. 2441 dans 21st Population Approach Group in Europe (PAGE) meeting, Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
 
Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2012. Clinical Pharmacokinetics, 51 (3) pp. 187-201. Peer-reviewed.
 
Therapeutic drug monitoring of targeted anticancer therapy. Tyrosine kinase inhibitors and selective estrogen receptor modulators: A clinical pharmacology laboratory perspective
Decosterd L.A., Dahmane E., Neeman M., Buclin T., Csajka C., Haouala A., Widmer N., 2012. pp. 197-250 dans Xu Q.A, Madden T.L. (eds.) LC-MS in drug bioanalysis chap. 9, Springer.
 
Therapeutic drug monitoring of targeted anticancer therapy. Tyrosine kinase inhibitors and selective oestrogen receptor modulators: A clinical pharmacology laboratory perspective
Decosterd LA Dahmane E Neeman M Buclin T Csajka C Haouala A Widmer N, 2012. pp. 197-250 dans LC-MS in Drug Bioanalysis, Springer.
 
Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.
Arab-Alameddine M., Décosterd L.A., Buclin T., Telenti A., Csajka C., 2011. Expert Opinion On Drug Metabolism and Toxicology, 7 (5) pp. 609-622.
Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
Fayet Mello A., Buclin T., Franc C., Colombo S., Cruchon S., Guignard N., Biollaz J., Telenti A., Decosterd L.A., Cavassini M., 2011. Journal of Antimicrobial Chemotherapy, 66 (7) pp. 1573-1581.
 
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.
Haouala A., Widmer N., Duchosal M.A., Montemurro M., Buclin T., Decosterd L.A., 2011. Blood, 117 (8) pp. e75-e87. Peer-reviewed.
 
Improvement of therapeutic drug monitoring of imatinib by Bayesian prediction of trough levels. Personalized drug dosage
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2011. p. 478 dans 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), Therapeutic Drug Monitoring. Peer-reviewed.
 
Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy.
Magenta L., Dell-Kuster S., Richter W.O., Young J., Hasse B., Flepp M., Hirschel B., Vernazza P., Evison J., Cavassini M. et al., 2011. Aids Research and Human Retroviruses, 27 (5) pp. 525-533.
 
P-glycoprotein modulation by valspodar and cyclosporin does not increase tumor uptake of doxorubicin administered via isolated lung perfusion to rats bearing sarcoma lung metastases.
Kuemmerle A., Yan H., Krueger T., Buclin T., Braissant O., Henry H., Ris H.B., Decosterd L.A., 2011. Anticancer Research, 31 (6) pp. 2121-2128.
 
Personalized drug dosage: Monitoring of imatinib concentration with a Bayesian interpretation tool
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2011. dans Nano-Tera Annual Plenary Meeting.
 
Photodynamic therapy enhances liposomal doxorubicin distribution in tumors during isolated perfusion of rodent lungs.
Cheng C., Wang Y., Haouala A., Debefve E., Andrejevic Blant S., Krueger T., Gonzalez M., Ballini J.P., Peters S., Decosterd L. et al., 2011. European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes, 47 (4) pp. 196-204.
 
Successful efavirenz dose reduction guided by therapeutic drug monitoring.
Fayet Mello A., Buclin T., Decosterd L.A., Delhumeau C., di Iulio J., Fleurent A., Schneider M.P., Cavassini M., Telenti A., Hirschel B. et al., 2011. Antiviral Therapy, 16 (2) pp. 189-197.
 
Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.
Buclin T., Widmer N., Biollaz J., Decosterd L.A., 2011. Lancet Oncology, 12 (1) pp. 9-11. Peer-reviewed.
 
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R., di Iulio J., Fayet A., Colombo S., Martinez R., Marzolini C., Furrer H., Vernazza P., Calmy A., Cavassini M. et al., 2010. Pharmacogenetics and Genomics, 20 (4) pp. 217-230.
 
An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.
Dahmane E., Mercier T., Zanolari B., Cruchon S., Guignard N., Buclin T., Leyvraz S., Zaman K., Csajka C., Decosterd L.A., 2010. Journal of Chromatography. B, Analytical Technologies In the Biomedical and Life Sciences, 878 (32) pp. 3402-3414.
 
Cardiovascular drug interactions with tyrosine kinase inhibitors
Haouala A., Widmer N., Montemurro M., Buclin T., Decosterd L., 2010. Cardiovascular Medicine, 13 (5) pp. 147-154. Peer-reviewed.
 
Determination of oseltamivir and oseltamivir carboxylate in human plasma by liquid chromatography-tandem mass spectrometry
Aouri M., Zanolari B., Meylan P., Ivanyuk A., Buclin T., Decosterd L.A., Widmer N., 2010. pp. 25S dans Réunion annuelle Société Suisse de Médecine Intensive, Société Suisse d'Infectiologie, Société Suisse d'Hygiène Hospitalière, Société Suisse de Pharmacologie et Toxicologie Cliniques, Communauté Suisse d'intérêts pour soins intensifs, Invité: Société Suisse de Transplantation, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Feasibility of Therapeutic Drug Monitoring (TDM) for Imatinib: Preliminary considerations on the dosage adjustment approach for CML patients enrolled in the Imatinib Concentration Monitoring (I-COME) study
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. pp. 90S dans 78. Jahresversammlung der Schweizerischen Gesellschaft für Innere Medizin, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Ganciclovir exposure under a 450mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study.
Manuel O., Pascual M., Perrottet N., Lamoth F., Venetz J.P., Decosterd L.A., Buclin T., Meylan P.R., 2010. Clinical Transplantation, 24 (6) pp. 794-800.
Imatinib plasma levels: correlation with clinical benefit in GIST patients.
Widmer N., Decosterd L.A., Csajka C., Montemurro M., Haouala A., Leyvraz S., Buclin T., 2010. British Journal of Cancer, 102 (7) pp. 1198-1199. Peer-reviewed.
 
Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures.
Scherrer A.U., von Wyl V., Fux C.A., Opravil M., Bucher H.C., Fayet A., Decosterd L.A., Hirschel B., Khanlari B., Yerly S. et al., 2010. Journal of Acquired Immune Deficiency Syndromes, 53 (4) pp. 464-471.
 
Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin.
Decosterd L.A., Rochat B., Pesse B., Mercier T., Tissot F., Widmer N., Bille J., Calandra T., Zanolari B., Marchetti O., 2010. Antimicrobial Agents and Chemotherapy, 54 (12) pp. 5303-5315. Peer-reviewed.
 
Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
Widmer N., Meylan P., Ivanyuk A., Aouri M., Decosterd L.A., Buclin T., 2010. Clinical Pharmacokinetics, 49 (11) pp. 741-765. Peer-reviewed.
 
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
Neely Michael, Decosterd Laurent, Fayet Aurelie, Lee Janice Soo Fern, Margol Ashley, Kanani Meera, di Iulio Julia, von Schoen-Angerer Tido, Jelliffe Roger, Calmy Alexandra, 2010. Antimicrobial Agents and Chemotherapy, 54 (11) pp. 4619-4625.
 
Photodynamic therapy selectively enhances liposomal doxorubicin uptake in sarcoma tumors to rodent lungs.
Cheng C., Debefve E., Haouala A., Andrejevic-Blant S., Krueger T., Ballini J.P., Peters S., Decosterd L., van den Bergh H., Wagnieres G. et al., 2010. Lasers in Surgery and Medicine, 42 (5) pp. 391-399.
Prospective assessment of CYP2D6 by genotyping, phenotyping and measurement of tamoxifen, PD 05-09 4-hydroxy-tamoxifen and endoxifen in breast cancer patients treated with tamoxifen.
Zaman K., Dahmane E., Perey L., Buclin T., Berthod G., Bodmer A., Galmiche M., Leyvraz S., Eap C., Csajka C. et al., 2010. dans 33rd Annual San Antonio Breast Cancer Symposium.
Prospective monitoring of cefepime in intensive care unit adult patients.
Chapuis T.M., Giannoni E., Majcherczyk P.A., Chioléro R., Schaller M.D., Berger M.M., Bolay S., Décosterd L.A., Bugnon D., Moreillon P., 2010. Critical Care, 14 (2) pp. R51.
 
Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.
Gutmann C., Cusini A., Günthard H.F., Fux C., Hirschel B., Decosterd L.A., Cavassini M., Yerly S., Vernazza P.L., Swiss HIV Cohort Study (SHCS), 2010. Aids, 24 (15) pp. 2347-2354.
Residual antimalarial concentrations before treatment in patients with malaria from Cambodia: indication of drug pressure.
Hodel Eva Maria, Genton Blaise, Zanolari Boris, Mercier Thomas, Duong Socheat, Beck Hans-Peter, Olliaro Piero, Decosterd Laurent A., Ariey Frederic, 2010. Journal of Infectious Diseases, 202 (7) pp. 1088-1094.
 
siRNA-Mediated Knock-Down of P-Glycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors.
Haouala A., Rumpold H., Untergasser G., Buclin T., Ris H.B., Widmer N., Decosterd L.A., 2010. Drug Metabolism Letters, 4 (2) pp. 114-119. Peer-reviewed.
Suivi thérapeutique de l'imatinib
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. Forum Medical Suisse, 10 (23) pp. 403-406. Peer-reviewed.
 
Therapeutic Drug Monitoring (TDM) of Imatinib: Effectiveness of Bayesian dose adjustment for CML patients enrolled in the Imatinib Concentration Monitoring (I-COME) study
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. pp. 28S dans Réunion annuelle Société Suisse de Médecine Intensive, Société Suisse d'Infectiologie, Société Suisse d'Hygiène Hospitalière, Société Suisse de Pharmacologie et Toxicologie Cliniques, Communauté Suisse d'intérêts pour soins intensifs, Invité: Société Suisse de Transplantation, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia.
Widmer N., Gotta V., Haouala A., Decosterd L.A., 2010. Leukemia Research, 34 (6) pp. 698-699. Peer-reviewed.
 
Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.
Rochat B., Pascual A., Pesse B., Lamoth F., Sanglard D., Decosterd L.A., Bille J., Marchetti O., 2010. Antimicrobial Agents and Chemotherapy, 54 (12) pp. 5074-5081.
Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
Perrottet Nancy, Manuel Oriol, Lamoth Frederic, Venetz Jean-Pierre, Sahli Roland, Decosterd Laurent A., Buclin Thierry, Pascual Manuel, Meylan Pascal, 2010. BMC Infectious Diseases, 10 p. 2.
Residual antimalarials in malaria patients from Tanzania--implications on drug efficacy assessment and spread of parasite resistance.
Hodel E.M., Kabanywanyi A.M., Malila A., Zanolari B., Mercier T., Beck H.P., Buclin T., Olliaro P., Decosterd L.A., Genton B., 2009/12/14. PloS one, 4 (12) pp. e8184. Peer-reviewed.
Tamoxifen metabolism and the impact of Tamoxifen dose on the level of the active metabolites in endocrine sensitive breast cancer patients
Dahmane Elyes, Csajka Chantal, Decosterd Laurent, Mercier Thomas, Zanolari Boris, Eap Chin, Buclin Thierry, Galmiche Marie, Zaman Khalil, 2009/09. dans ''Frontiers in drug discovery and development'' : 24ème séminaire, 3ème cycle, en sciences pharmaceutiques.
 
A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.
Fayet A., Béguin A., Zanolari B., Cruchon S., Guignard N., Telenti A., Cavassini M., Günthard H.F., Buclin T., Biollaz J. et al., 2009. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 877 (11-12) pp. 1057-1069.
A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites
Kuemmerle A., Decosterd L. A., Buclin T., Liénard D., Stupp R., Chassot P. G., Mosimann F., Lejeune F., 2009. Cancer Chemotherapy and Pharmacology, 63 (2) pp. 331-341. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Swiss University